SV2002000462A - 5-cloro-3-(4-metansulfonilfenilo)-6'-metil-/2,3'/bipiridinilo en forma cristalina pura y proceso para la sintesis ref. b.12483/lg - Google Patents

5-cloro-3-(4-metansulfonilfenilo)-6'-metil-/2,3'/bipiridinilo en forma cristalina pura y proceso para la sintesis ref. b.12483/lg

Info

Publication number
SV2002000462A
SV2002000462A SV2001000462A SV2001000462A SV2002000462A SV 2002000462 A SV2002000462 A SV 2002000462A SV 2001000462 A SV2001000462 A SV 2001000462A SV 2001000462 A SV2001000462 A SV 2001000462A SV 2002000462 A SV2002000462 A SV 2002000462A
Authority
SV
El Salvador
Prior art keywords
metansulfonilfenilo
bipiridinyl
chlorine
methyl
crystalline form
Prior art date
Application number
SV2001000462A
Other languages
English (en)
Spanish (es)
Inventor
Louis S Crocker
Ian W Davies
Andrew Kotliar
Richard G Osifchin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2002000462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2002000462A publication Critical patent/SV2002000462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SV2001000462A 2000-05-26 2001-05-23 5-cloro-3-(4-metansulfonilfenilo)-6'-metil-/2,3'/bipiridinilo en forma cristalina pura y proceso para la sintesis ref. b.12483/lg SV2002000462A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26

Publications (1)

Publication Number Publication Date
SV2002000462A true SV2002000462A (es) 2002-03-08

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000462A SV2002000462A (es) 2000-05-26 2001-05-23 5-cloro-3-(4-metansulfonilfenilo)-6'-metil-/2,3'/bipiridinilo en forma cristalina pura y proceso para la sintesis ref. b.12483/lg

Country Status (48)

Country Link
EP (1) EP1296951B1 (forum.php)
JP (2) JP3665053B2 (forum.php)
KR (1) KR100757699B1 (forum.php)
CN (1) CN1227233C (forum.php)
AR (1) AR028577A1 (forum.php)
AT (1) ATE483687T1 (forum.php)
AU (2) AU2001264804B2 (forum.php)
BG (1) BG65855B1 (forum.php)
BR (1) BRPI0111140B8 (forum.php)
CA (1) CA2410234C (forum.php)
CR (1) CR6606A (forum.php)
CY (1) CY1111440T1 (forum.php)
CZ (1) CZ20023888A3 (forum.php)
DE (1) DE60143197D1 (forum.php)
DK (1) DK1296951T3 (forum.php)
EA (1) EA004809B1 (forum.php)
EE (1) EE05242B1 (forum.php)
EG (1) EG24189A (forum.php)
ES (1) ES2351958T3 (forum.php)
GC (1) GC0000362A (forum.php)
GE (1) GEP20053492B (forum.php)
GT (1) GT200100091A (forum.php)
HN (1) HN2001000110A (forum.php)
HR (1) HRP20020934B1 (forum.php)
HU (1) HU228423B1 (forum.php)
IL (1) IL152582A0 (forum.php)
IN (2) IN2002CH02089A (forum.php)
IS (1) IS2806B (forum.php)
JO (1) JO2216B1 (forum.php)
MA (1) MA26919A1 (forum.php)
ME (1) ME00428B (forum.php)
MX (1) MX230696B (forum.php)
MY (1) MY123569A (forum.php)
NO (1) NO324495B1 (forum.php)
NZ (1) NZ522394A (forum.php)
PA (1) PA8516901A1 (forum.php)
PE (1) PE20011324A1 (forum.php)
PH (1) PH12001001175B1 (forum.php)
PL (1) PL358153A1 (forum.php)
PT (1) PT1296951E (forum.php)
RS (1) RS51541B (forum.php)
SI (1) SI1296951T1 (forum.php)
SK (1) SK287174B6 (forum.php)
SV (1) SV2002000462A (forum.php)
TW (1) TWI303634B (forum.php)
UA (1) UA73355C2 (forum.php)
WO (1) WO2001092230A1 (forum.php)
ZA (1) ZA200209558B (forum.php)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037833A1 (en) 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
MY163020A (en) 2009-02-27 2017-07-31 Cadila Healthcare Ltd A process for the preparation of etoricoxib
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
WO2014041558A2 (en) * 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
EP2887924B1 (en) 2012-08-27 2017-03-29 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CN1152863C (zh) * 1996-07-18 2004-06-09 麦克弗罗斯特(加拿大)公司 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物
SI1071745T1 (en) * 1998-04-24 2004-10-31 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
WO2001037833A1 (en) * 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Also Published As

Publication number Publication date
PT1296951E (pt) 2010-12-07
RS51541B (sr) 2011-06-30
MY123569A (en) 2006-05-31
TWI303634B (en) 2008-12-01
JP2004501116A (ja) 2004-01-15
WO2001092230A1 (en) 2001-12-06
YU89402A (sh) 2005-11-28
AU2001264804B2 (en) 2006-04-06
CY1111440T1 (el) 2015-08-05
PL358153A1 (en) 2004-08-09
PA8516901A1 (es) 2002-04-25
JP4142621B2 (ja) 2008-09-03
NO20025674D0 (no) 2002-11-26
BG65855B1 (bg) 2010-03-31
PH12001001175B1 (en) 2006-08-10
BR0111140A (pt) 2005-01-11
IL152582A0 (en) 2003-05-29
HN2001000110A (es) 2002-03-06
NO324495B1 (no) 2007-10-29
EP1296951B1 (en) 2010-10-06
EA200201264A1 (ru) 2003-04-24
EE05242B1 (et) 2009-12-15
ME00428B (me) 2011-10-10
HRP20020934A2 (en) 2005-02-28
IS6630A (is) 2002-11-20
ZA200209558B (en) 2003-10-28
CZ20023888A3 (cs) 2003-02-12
CN1443168A (zh) 2003-09-17
JO2216B1 (en) 2004-10-07
AU6480401A (en) 2001-12-11
MA26919A1 (fr) 2004-12-20
NZ522394A (en) 2004-05-28
ATE483687T1 (de) 2010-10-15
ES2351958T3 (es) 2011-02-14
HU228423B1 (en) 2013-03-28
BRPI0111140B8 (pt) 2021-05-25
AR028577A1 (es) 2003-05-14
SI1296951T1 (sl) 2011-01-31
MXPA02011619A (es) 2003-03-27
EE200200655A (et) 2004-08-16
KR20030003762A (ko) 2003-01-10
CA2410234C (en) 2008-05-13
GEP20053492B (en) 2005-04-25
EA004809B1 (ru) 2004-08-26
HK1058932A1 (en) 2004-06-11
IN2007CH05103A (forum.php) 2008-08-27
DK1296951T3 (da) 2011-01-24
HUP0302336A2 (hu) 2003-11-28
KR100757699B1 (ko) 2007-09-13
BRPI0111140B1 (pt) 2018-03-13
GC0000362A (en) 2007-03-31
MX230696B (es) 2005-09-19
EG24189A (en) 2008-10-08
SK287174B6 (sk) 2010-02-08
IN2002CH02089A (forum.php) 2005-02-25
CA2410234A1 (en) 2001-12-06
PE20011324A1 (es) 2002-01-28
NO20025674L (no) 2002-11-26
DE60143197D1 (de) 2010-11-18
EP1296951A1 (en) 2003-04-02
GT200100091A (es) 2001-12-28
CN1227233C (zh) 2005-11-16
JP3665053B2 (ja) 2005-06-29
CR6606A (es) 2006-02-06
HRP20020934B1 (en) 2012-01-31
UA73355C2 (en) 2005-07-15
SK16702002A3 (sk) 2003-05-02
JP2005047927A (ja) 2005-02-24
IS2806B (is) 2012-09-15
BG107237A (bg) 2003-05-30

Similar Documents

Publication Publication Date Title
SV2002000462A (es) 5-cloro-3-(4-metansulfonilfenilo)-6'-metil-/2,3'/bipiridinilo en forma cristalina pura y proceso para la sintesis ref. b.12483/lg
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
BR0308979A (pt) Derivados de indolilmaleimida
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
WO2004048345A3 (en) 2,5-diketopiperazines for the treatment of obesity
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
TW200722100A (en) A therapeutic agent for a β related disorders
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
DE60221813D1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
DE60114640D1 (en) Antithrombosemittel
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
UY27554A1 (es) Compuestos azapolicíclicos condensados con arilo
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
PT1105392E (pt) Processo para a preparacao de intermediarios de imidazodiazepina
ECSP014078A (es) Derivados de sulfonamida
TH82626A (th) สารประกอบชนิดใหม่
TH80175A (th) ไดแอซีเรนสำหรับใช้ในการบำบัดโรคเรื้อนกวาง
ECSP992887A (es) Biciclo (2.2.1) heptanos y compuestos relacionados
EA200601842A1 (ru) D-гомо-17-хлор-16(17)-ен-стероиды

Legal Events

Date Code Title Description
FG Grant